Elevated rheumatoid factor and long term risk of rheumatoid arthritis: A prospective cohort study

BMJ (Online)

Volumn 345, Issue 7878, 2012, Pages

  Nielsen, Sune F ^a,b   Bojesen, Stig E ^a,b,c   Schnohr, Peter ^c   Nordestgaard, Børge G ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; RHEUMATOID FACTOR;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT REFERRAL; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SMOKING; AGE; BLOOD; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; RISK FACTORS; ROC CURVE; SEX FACTORS; SMOKING; YOUNG ADULT;

EID: 84867094057     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e5244     Document Type: Article

References (38)

1. Gaston JSH. Rheumatic diseases, immunological mechanisms and prospects for new therapies. University of Cambridge, 1999.
2. Neovius M, Simard JF, Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011;70:624-9.
3. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative initiative. Arthritis Rheum 2010;62:2569-81.
4. Cohen SB. Targeting the B cell in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010;24:553-63.
5. Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 2010;73:431-8.
6. Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P, et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 2009;4:e7556.
7. Verstappen SMM, Albada-Kuipers GAV, Bijlsma JWJ, Blaauw AAM, Schenk Y, Haanen HCM, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005;64:38-43. (Pubitemid 40075272)
8. Balsa A, del Amo J, Blanco F, Caliz R, Silva L, Sanmarti R, et al. Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms. Rheumatology 2010;49:458-66.
9. Deane KD, O'Donnell CI, Hueber W, Majka DS, Lazar AA, Derber LA, et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 2010;62:3161-72.
10. Kuriya B, Cheng CK, Chen HM, Bykerk VP. Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis. Ann Rheum Dis 2009;68:1482-5.
11. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American-Rheumatism-Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
12. Boutry N, do Carmo CCM, Flipo RM, Cotten A. Early rheumatoid arthritis and its differentiation from other joint abnormalities. Eur J Radiol 2009;71:217-24.
13. Machold KP, Stamm TA, Eberl GJM, Nell VKP, Dunky A, Uffmann M, et al. Very recent onset arthritis - clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002;29:2278-87. (Pubitemid 35266017)
14. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-9. (Pubitemid 44816920)
15. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Non-fasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308. (Pubitemid 47080484)
16. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community-21 year follow-up of 12 000 men and women from the Copenhagen City Heart Study. Eur Heart J 2002;23:620-6. (Pubitemid 35204246)
17. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-8. (Pubitemid 29299976)
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
19. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:3-46.
20. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. JCO 2007;25:57-63. (Pubitemid 350003051)
21. Orsted D, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur J Cancer 2011;47:504.
22. Turesson C, Jacobsson LTH, Sturfelt G, Matteson EL, Mathsson L, Ronnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007;66:59-64. (Pubitemid 46044861)
23. Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol 2009;38:166-72.
24. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Rantapaa-Dahlqvist S. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008;35:1002-8. (Pubitemid 351813144)
25. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Scand J Rheumatol 2006;35:29.
26. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9. (Pubitemid 39120359)
27. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808. (Pubitemid 351650500)
28. Tamai M, Kawakami A, Iwamoto N, Arima K, Aoyagi K, Eguchi K. Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism. Scand J Rheumatol 2010;39:287-91.
29. Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM 2010;103:139-46.
30. Ursum J, Bos WH, van Dillen N, Dijkmans BAC, van Schaardenburg D. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010;12(1):R8.
31. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 2003;42:677-80. (Pubitemid 37220878)
32. Rantapaa-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9. (Pubitemid 37280601)
33. Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid-arthritis. J Rheumatol 1991;18:1282-4.
34. Nielen MMJ, van Schaardenburg D, Reesink HW, Van de Stadt RJ, horst-Bruinsma IE, de Koning MHMT, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis - a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
35. Fischer KM. Hypothesis: tobacco use is a risk factor in rheumatoid arthritis. Med Hypotheses 1991;34:116-7.
36. Hutchinson D, Shepstone L, Moots R, Lear JT, Lynch. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis 2001;60:223-7. (Pubitemid 32260603)
37. Baka Z, Burzas E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther 2009;11:238.
38. Pedersen M, Klarlund M, Jacobsen S, Svendsen AJ, Frisch M. Validity of rheumatoid arthritis diagnoses in the Danish National Patient Registry. Eur J Epidemiol 2004;19:1097-103.